KALRAY
11.5.2023 07:46:32 CEST | Business Wire | Press release
Kalray (Euronext Growth Paris : ALKAL), a leading provider of hardware and software technologies for high-performance, data-centric computing markets, from cloud to edge, is pleased to announce that the IP-CUBE project, led by Kalray, has won the "Technological Maturation and Demonstration of Embedded Artificial Intelligence Solutions" call for projects under the "France Relance 2030 - Future Investments" plan. Kalray's next-generation high-performance, low-power DPU processor is at the heart of the project.
ARTIFICIAL INTELLIGENCE, EDGE COMPUTING, AND SEMICONDUCTORS - MAJOR CHALLENGES FOR THE COMING DECADES
Use cases linked to artificial intelligence (AI) are developing exponentially. Whereas the massive diffusion of AI currently relies heavily on the use of computing resources located in the cloud, there is a growing need for solutions allowing the use of AI in a more reactive, more secure, and less energy hungry way for users. These AI solutions will be deployed in particular in embedded systems as well as local data centers ("edge data centers") that aim to process data closer to where it is generated, as efficiently as possible. This is known as "edge computing", a fast-growing market estimated to be worth several billion Euros1 by 2025 that is comprised of vast areas of the economy such as the telecommunications, new generation of manufacturing, IoT, automotive industry, aerospace, and defense.
However, embedded AI and edge computing require new types of processors and new semiconductor technologies to process and accelerate AI algorithms and meet new technological challenges; high performance, but also low power consumption, low latency, and security.
The IP-CUBE project, led by Kalray, aims to meet these challenges and create the foundations of a French semiconductor ecosystem in the field of edge computing and embedded AI, based on the national leaders in the field, namely Arteris, Kalray, Secure-IC, and Thales.
FINANCING OF STRATEGIC AND SOVEREIGN TECHNOLOGIES
The IP-CUBE project, totaling €36.7M, will directly participate in funding key technology building blocks in this area, particularly Kalray's next-generation Dolomites™ DPU processor for the amount of €10M, Arteris' next-generation NoC (Network-On-Chip), Secure-IC's specialized IP (intellectual property) development for security, and Thales' RISC-V-based low-power component development.
"We are very pleased that the IP-CUBE project has been selected. It will not only allow us to finance a significant part of the development of our 4th generation DPU processor, but also to develop, in collaboration with our partners, the French know-how and technologies in the strategic semiconductor fields around AI applications," said Eric Baissus, CEO of Kalray.
Kalray is the only company in France and Europe to offer DPU (Data Processing Unit) processors, a new type of low-power, high-performance programmable processor, capable of processing data on the fly and multiple applications (AI and others) in parallel, while providing the required security features.
As a pioneer in the field, Kalray has developed a unique expertise and an innovative technology based on its patented MPPA® (Massively Parallel Processor Array) architecture, the cornerstone of its DPU processors and acceleration cards. This technological leadership enables Kalray to offer a serious French and European alternative to the predominantly American or Chinese technology players. At the end of 2022, Kalray announced the signing of a framework contract with a major NASDAQ-listed customer to supply its high-performance DPU cards.
"In the current geopolitical context, the semiconductor industry has become essential, both in terms of production tools and technological know-how for designing processors. France and Europe need production plants, but they also need companies capable of designing the processors that will be manufactured in these plants, and that will be at the heart of tomorrow's markets. We are delighted with the strong support from France through the IP-CUBE project, and the support from Europe through other collaborative projects, such as the EPI (European Processor Initiative), in which Kalray is also participating, to help us achieve our ambition of making Kalray the future European Nvidia," concluded Eric Baissus.
ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data centric computing markets, from cloud to edge.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Science, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
| ___________________________________ | ||
1 |
McKinsey – AI-related semiconductor market. |
|
NVIDIA: https://blogs.nvidia.com/blog/2019/10/22/what-is-edge-computing/ |
||
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510006021/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom